Research ArticleBasic Science Investigations
DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice
Cristina Müller, Harriet Struthers, Christian Winiger, Konstantin Zhernosekov and Roger Schibli
Journal of Nuclear Medicine January 2013, 54 (1) 124-131; DOI: https://doi.org/10.2967/jnumed.112.107235
Cristina Müller
1Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland
Harriet Struthers
2Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
Christian Winiger
2Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
Konstantin Zhernosekov
1Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland
3Laboratory of Radiochemistry and Environmental Chemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland
Roger Schibli
1Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland
2Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 54, Issue 1
January 1, 2013
DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice
Cristina Müller, Harriet Struthers, Christian Winiger, Konstantin Zhernosekov, Roger Schibli
Journal of Nuclear Medicine Jan 2013, 54 (1) 124-131; DOI: 10.2967/jnumed.112.107235
DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice
Cristina Müller, Harriet Struthers, Christian Winiger, Konstantin Zhernosekov, Roger Schibli
Journal of Nuclear Medicine Jan 2013, 54 (1) 124-131; DOI: 10.2967/jnumed.112.107235
Jump to section
Related Articles
Cited By...
- Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors
- Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
- Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents
- Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice
- Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent {beta}--Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate
- 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy